“Understanding how inflammation changes in people on elexacaftor/tezacaftor/ivacaftor (ETI) therapy is important because neutrophilic inflammation is associated with, and predictive of, several key clinical outcomes in [cystic fibrosis (CF)] including bronchiectasis, lung function decline, future pulmonary exacerbations and shortened survival,” Scott D. Sagel, professor of pediatrics-pulmonary medicine at the University of Colorado School of Medicine, told Healio.